Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
Preservation and Transfer of Hepatitis B Virus Immunity After Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease Patients (Protect Study).

We hypothesize, that sickle cell disease (SCD) patients ending with mixed mononuclear chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will preserve their immune response to vaccinations administered prior to the transplantation and will therefore not need to be revaccinated.

Locations

1 Netherlands site

Age

16 Years to 60 Years Years

Phase

Not Applicable

LEARN MORE
Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in Matched Sibling Donor Allogeneic HSCT in Adult Sickle Cell Patients

In this study the investigators will prospectively investigate whether the addition of a 3-months long preconditioning with azathioprine to the alemtuzumab/TBI non-myeloablative conditioning results in improved disease-free survival and donor chimerism after allo-SCT in SCD patients.

Locations

1 Netherlands site

Age

16 Years to 60 Years Years

Genotypes

2

LEARN MORE
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Treatment Effect of Voxelotor on Neurocognitive Function in Pediatric Participants 8 to < 18 Years of Age With Sickle Cell Disease

This is a Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to assess the treatment effect of voxelotor on neurocognitive function as assessed by the National Institute of Health (NIH) Toolbox Cognition Module of executive abilities in pediatric participants (8 to < 18 years) with SCD.

Locations

1 United States site

Age

8 Years to 17 Years Years

Phase

Phase 3

LEARN MORE
Prevalence and Pathophysiology of Systemic Arterial Pressure Abnormalities in Childhood Sickle Cell Disease

It is usually found that the blood pressure of adults with sickle cell disease is lower than in non-sickle cell patients.

Locations

1 France site

Age

6 Years to 18 Years Years

LEARN MORE
Fitness Intervention Trial in Adults With Sickle Cell Disease (SCD Fit): A Feasibility Study

The purpose of this project is to develop novel approaches to promote health and longevity while enhancing quality of life among persons with Sickle cell disease (SCD).

Locations

1 United States site

Age

18 Years to Years

Phase

Not Applicable

LEARN MORE
Pilot Evaluation of a Telehealth Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Sickle Cell Disease

Sickle cell disease (SCD) is a group of inherited blood disorders affecting 100,000 individuals in the United States.

Locations

1 United States site

Age

13 Years to Years

Phase

Not Applicable

LEARN MORE
Observational Study of Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

Background: Sickle Cell Disease (SCD) causes blood cells form a crescent shape.

Locations

1 United States site

Age

18 Years to Years

LEARN MORE
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, PK, and Food Effect of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Healthy Participants.

This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.

Locations

1 United States site

1 Australia site

Age

18 Years to 55 Years Years

Phase

Phase 1

LEARN MORE
A Phase I/II Study of GPH101 in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease

This study is a first-in-human, single-arm, open-label Phase I/II study of GPH101 in approximately 15 participants, diagnosed with severe Sickle Cell Disease.

Locations

3 United States sites

Age

12 Years to 40 Years Years

Phase

Phase 1/Phase 2

LEARN MORE
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)

This is a multicenter, prospective, single-arm observational non-interventional study (NIS), which will be conducted in various countries in the Middle East and India.

Locations

1 Bahrain site

1 India site

1 Kuwait site

1 Qatar site

1 Saudi Arabia site

1 United Arab Emirates site

Age

16 Years to 99 Years Years

LEARN MORE